Mechanism of Shexiang Baoxin pill in the treatment of atherosclerosis based on network pharmacology
10.12206/j.issn.2097-2024.202112001
- VernacularTitle:基于网络药理学探讨麝香保心丸治疗动脉粥样硬化作用机制
- Author:
Zhicong WANG
1
,
2
;
Bin XIE
2
;
Xing YUAN
2
;
Xike XU
2
;
Runhui LIU
1
,
2
Author Information
1. Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China
2. School of Pharmacy, Naval Medical University, Shanghai 200433, China.
- Keywords:
Shexiang Baoxin pill;
network pharmacology;
atherosclerosis;
mechanism
- From:
Journal of Pharmaceutical Practice
2023;41(5):296-301
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the mechanism of Shexiang Baoxin pill in the treatment of atherosclerosis, and to provide a theoretical basis for long-term clinical application. Methods The chemical components and targets of Shexiang Baoxin pill were collected and screened by TCMSP, TCMID, ETCM and BATMAN databases. The targets related to atherosclerosis were collected and screened by DisGeNet, OMIM, TCMSP, DrugBank and DisGeNet. Drug-compound target network and protein-protein interaction network were constructed. Go and KEGG enrichment analysis of Shexiang Baoxin pill in the treatment of atherosclerosis were carried out on MetaScape platform. Results 114 potential therapeutic components of Shexiang Baoxin pill on atherosclerosis were selected, corresponding to 175 targets. The results of network analysis showed that the main active components of Shexiang Baoxin pill were chenodeoxycholic acid, ursodeoxycholic acid, cinnamaldehyde and ginsenoside Rb1. The results of pathway enrichment showed that the anti-atherosclerotic mechanism of Shexiang Baoxin pill was related to the regulation of immunity, inflammation, and metabolism. Conclusion The active components of Shexiang Baoxin pill could act on ALB, INS, AKT1, ACTB, TNF, IL-6 and other targets, regulating multiple pathways to achieve the therapeutic effect on atherosclerosis.
